• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

未接种疫苗的美国成年人对暂停使用强生-杨森 COVID-19 疫苗的官方信息的反应：横断面调查研究。

Response of Unvaccinated US Adults to Official Information About the Pause in Use of the Johnson & Johnson-Janssen COVID-19 Vaccine: Cross-Sectional Survey Study.

机构信息

Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, United States.

Data Science Initiative, Harvard University, Allston, MA, United States.

出版信息

J Med Internet Res. 2024 Apr 1;26:e41559. doi: 10.2196/41559.

DOI:10.2196/41559
PMID:38557597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11019423/
Abstract

Using a rapid response web-based survey, we identified gaps in public understanding of the Centers for Disease Control and Prevention's messaging about the pause in use of the Johnson & Johnson-Janssen COVID-19 vaccine and estimated changes in vaccine hesitancy using counterfactual questions.

摘要

我们使用快速反应的网络调查，发现公众对疾病控制与预防中心（CDC）关于暂停使用强生-杨森（Johnson & Johnson-Janssen）COVID-19 疫苗的信息存在理解上的差距，并使用反事实问题来估计疫苗犹豫率的变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a2/11019423/0c2266088fb6/jmir_v26i1e41559_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a2/11019423/0c2266088fb6/jmir_v26i1e41559_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a2/11019423/0c2266088fb6/jmir_v26i1e41559_fig1.jpg

相似文献

1
Response of Unvaccinated US Adults to Official Information About the Pause in Use of the Johnson & Johnson-Janssen COVID-19 Vaccine: Cross-Sectional Survey Study.未接种疫苗的美国成年人对暂停使用强生-杨森 COVID-19 疫苗的官方信息的反应：横断面调查研究。
J Med Internet Res. 2024 Apr 1;26:e41559. doi: 10.2196/41559.
2
Impact of vaccine pause due to Thrombosis with thrombocytopenia syndrome (TTS) following vaccination with the Ad26.COV2.S vaccine manufactured by Janssen/Johnson & Johnson on vaccine hesitancy and acceptance among the unvaccinated population.由于强生公司生产的 Ad26.COV2.S 疫苗接种后出现血栓伴血小板减少综合征（TTS）而暂停疫苗接种，对未接种人群的疫苗犹豫和接受程度的影响。
PLoS One. 2022 Oct 11;17(10):e0274443. doi: 10.1371/journal.pone.0274443. eCollection 2022.
3
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021.使用杨森（强生） COVID-19 疫苗：免疫实践咨询委员会对美国 2021 年 12 月更新的临时建议。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):90-95. doi: 10.15585/mmwr.mm7103a4.
4
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.美国 2021 年 4 月：在报告接种强生（Johnson & Johnson）新冠疫苗的人群中出现血栓性血小板减少综合征后，免疫实践咨询委员会更新了强生疫苗的使用建议。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4.
5
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.强生（Johnson & Johnson）COVID-19 疫苗安全性监测-美国，2021 年 3 月-4 月。
MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):680-684. doi: 10.15585/mmwr.mm7018e2.
6
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.2021年3月至8月美国Moderna、辉瑞-生物科技公司和杨森（强生）疫苗在预防无免疫功能低下状况成年人新冠病毒肺炎住院方面的比较效果
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1.
7
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.在报告 Janssen（强生）和 mRNA COVID-19 疫苗（辉瑞-生物科技和莫德纳）成年受种者发生不良事件后使用 COVID-19 疫苗：免疫实践咨询委员会的更新-美国，2021 年 7 月。
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4.
8
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.同源和异源 COVID-19 加强针在接种 1 剂 Ad.26.COV2.S（强生[詹森]）疫苗后的有效性：成人因 COVID-19 前往急诊和紧急护理就诊和住院的情况 - VISION 网络，10 个州，2021 年 12 月至 2022 年 3 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 1;71(13):495-502. doi: 10.15585/mmwr.mm7113e2.
9
Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.暂停使用强生公司的 COVID-19 疫苗对美国疫苗犹豫的影响。
Vaccine. 2022 Jan 24;40(3):424-427. doi: 10.1016/j.vaccine.2021.11.085. Epub 2021 Dec 11.
10
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021.美国多发性硬化症成人对 COVID-19 疫苗的犹豫：2021 年疫苗初始推出期间的后续调查。
Mult Scler Relat Disord. 2021 Sep;54:103163. doi: 10.1016/j.msard.2021.103163. Epub 2021 Jul 22.

本文引用的文献

1
Changing the COVID-19 Conversation: It's About Language.改变关于新冠疫情的对话：关键在于语言。
JAMA Health Forum. 2021 Feb 1;2(2):e210020. doi: 10.1001/jamahealthforum.2021.0020.
2
Cross-platform spread: vaccine-related content, sources, and conspiracy theories in YouTube videos shared in early Twitter COVID-19 conversations.跨平台传播：在早期 Twitter COVID-19 对话中分享的 YouTube 视频中的疫苗相关内容、来源和阴谋论。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-13. doi: 10.1080/21645515.2021.2003647. Epub 2022 Jan 21.
3
Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
暂停使用强生公司的 COVID-19 疫苗对美国疫苗犹豫的影响。
Vaccine. 2022 Jan 24;40(3):424-427. doi: 10.1016/j.vaccine.2021.11.085. Epub 2021 Dec 11.
4
Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust.透明地沟通 COVID-19 疫苗的负面特征会降低其接受度，但会增加信任。
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29). doi: 10.1073/pnas.2024597118. Epub 2021 Jul 2.
5
Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine.评估接种Ad26.COV2.S疫苗后出现的罕见严重不良事件。
JAMA. 2021 Jun 22;325(24):2445-2447. doi: 10.1001/jama.2021.7637.
6
Beyond Politics - Promoting Covid-19 Vaccination in the United States.超越政治——在美国推广新冠疫苗接种
N Engl J Med. 2021 Feb 18;384(7):e23. doi: 10.1056/NEJMms2033790. Epub 2021 Jan 6.
7
Associations Between COVID-19 Misinformation Exposure and Belief With COVID-19 Knowledge and Preventive Behaviors: Cross-Sectional Online Study.新冠疫情虚假信息接触及相关信念与新冠疫情知识和预防行为之间的关联：横断面在线研究
J Med Internet Res. 2020 Nov 13;22(11):e22205. doi: 10.2196/22205.
8
Comparison of Readability of Official Public Health Information About COVID-19 on Websites of International Agencies and the Governments of 15 Countries.比较国际机构网站和 15 个国家政府网站上关于 COVID-19 的官方公共卫生信息的可读性。
JAMA Netw Open. 2020 Aug 3;3(8):e2018033. doi: 10.1001/jamanetworkopen.2020.18033.
9
From deficit to dialogue in science communication: The dialogue communication model requires additional roles from scientists.从科学传播的“赤字”到对话：对话传播模式需要科学家扮演更多角色。
EMBO Rep. 2020 Sep 3;21(9):e51278. doi: 10.15252/embr.202051278. Epub 2020 Aug 4.
10
Explaining risks: turning numerical data into meaningful pictures.解释风险：将数值数据转化为有意义的图表。
BMJ. 2002 Apr 6;324(7341):827-30. doi: 10.1136/bmj.324.7341.827.